New hope for hepatitis d: drug trial targets virus and liver health
NCT ID NCT06505928
First seen Dec 23, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests a new drug called hepalatide in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of the drug for 48 weeks, or wait for treatment. The goal is to see if the drug can lower the virus level and improve liver enzyme levels, which are signs of better liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
-
National cancer canter of Monglia
Ulaanbaatar, 13370, Mongolia
Conditions
Explore the condition pages connected to this study.